Trial reportFrontiers in immunology2025
On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information.
Trial report in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Glasgow prognostic score as a predictor of adjuvant nivolumab efficacy in esophageal squamous cell carcinoma.BMC gastroenterology · 2026Article
- Low prognostic nutritional index score is associated with lymph node metastasis in patients with breast cancer, whereas hemoglobin-albumin-lymphocyte-platelet score is not.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & aims: Hepatocellular carcinoma (HCC) is associated with high cancer-specific mortality. While immune-checkpoint inhibitors (ICIs) improved overall survival (OS) compared to tyrosine kinase inhibitors, biomarkers predicting response to ICI in HCC are lacking. This study investigates the prognostic value of serum-based prognostic scores in patients with HCC receiving atezolizumab and bevacizumab. Methods: This Results: The on-treatment mGPS, assessed 9 weeks post-treatment initiation, predicted OS with hazard ratios of 2.31 (95% CI 1.39-3.83, p < 0.001) for intermediate-risk and 3.40 (95% CI 3.07-5.59, p < 0.001) for high-risk, compared to low-risk groups, showing greater accuracy than RECIST imaging. Albumin, CRP, and IL-6 were individually good prognostic indicators, with albumin/CRP (ACR) and albumin/IL-6 (AIR) ratios having the highest prognostic power (c-index: ACR 0.66 (95% CI 0.61-0.71), AIR 0.67 (0.62-0.72), mGPS 0.62 (0.57-0.66)). Multivariable analysis confirmed serum-based scores' prognostic value independent of imaging. Serum-based scores significantly correlated with survival in patients with stable disease (SD, 79% of patients) or progressive disease (PD, 12% of patients). Conclusions: The on-treatment mGPS, as well as ACR and AIR, predicted outcomes in patients with HCC independent of and more accurately than radiological staging. Since, the mGPS is the most cost effective and widely validated score, we consider it best suited for clinical use. Prospective validation is needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.